Shakespeare Wealth Management LLC Makes New $223,000 Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

Shakespeare Wealth Management LLC acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 7,398 shares of the biopharmaceutical company’s stock, valued at approximately $223,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Bleakley Financial Group LLC acquired a new position in TG Therapeutics in the 4th quarter valued at about $245,000. Castellan Group purchased a new stake in TG Therapeutics during the 4th quarter worth approximately $8,539,000. Barclays PLC lifted its holdings in TG Therapeutics by 83.9% during the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock worth $8,117,000 after buying an additional 158,323 shares in the last quarter. JPMorgan Chase & Co. boosted its position in TG Therapeutics by 60.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock valued at $16,859,000 after buying an additional 270,286 shares during the period. Finally, Neo Ivy Capital Management acquired a new position in shares of TG Therapeutics in the third quarter worth $2,358,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Analyst Upgrades and Downgrades

TGTX has been the subject of several analyst reports. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX opened at $37.35 on Monday. The stock’s 50-day simple moving average is $35.27 and its 200-day simple moving average is $30.89. The firm has a market capitalization of $5.87 billion, a PE ratio of -373.46 and a beta of 2.13. TG Therapeutics, Inc. has a fifty-two week low of $12.93 and a fifty-two week high of $43.32. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. The company had revenue of $108.19 million for the quarter, compared to analysts’ expectations of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. As a group, equities research analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.